|
2024
|
Invention
|
Mutant kras modulators and uses thereof. 123456711234122, L, m, n, and r, are defined herein. Als... |
|
|
Invention
|
Inhibitors of btk and mutants thereof.
The disclosure includes compounds of Formula (I)
The di... |
|
|
Invention
|
Bcl-2 inhibitors.
The disclosure includes compounds of Formula (I)
The disclosure includes com... |
|
|
Invention
|
Bcl-2 inhibitors.
The disclosure includes compounds of Formula (A):
The disclosure includes co... |
|
2023
|
Invention
|
Bcl-2 inhibitors.
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, ... |
|
|
Invention
|
Mdm2 degrader. 122A34561234561233, m, n, r, s, and t, are defined herein. Also disclosed is a met... |
|
|
Invention
|
Condensed heterocyclic derivates as bcl-2 inhibitors for the treatment of neoplastic diseases.
T... |
|
|
Invention
|
Btk degrader.
The disclosure includes compounds of any one of Formulae (0)-(5), (11)-(24), (A)-(... |
|
|
Invention
|
Pan-kras inhibitors and uses thereof. 1231234560123122, m, n, and i, are defined herein. Also dis... |
|
|
Invention
|
Btk degrader. The disclosure includes compounds of any one of Formulae (0)-(5), (11 )-(24), (A)-(... |
|
2022
|
Invention
|
Bcl-2 inhibitors.
The disclosure includes compounds of Formulae (1) wherein Q1, Q2, Q3, Q4, Q5, ... |
|
|
Invention
|
Bcl-2 inhibitors. 12345678x123456791011x12455 are defined herein. Also disclosed is a method for ... |
|
|
Invention
|
Inhibitor of btk and mutants thereof.
The disclosure includes compounds of Formula (I) wherein W... |
|
|
Invention
|
Inhibitor of btk and mutants thereof. 01234123456012345677, are defined herein. Also disclosed is... |
|
|
Invention
|
Substituted pyrazines as inhibitors of btk, and mutants thereof. The disclosure includes compound... |
|
|
Invention
|
Isoquinoline derivatives as mutant egfr modulators and uses thereof.
The disclosure includes com... |
|
|
Invention
|
Isoquinoline derivatives as mutant egfr modulators and uses thereof. AB123444, W1, W2, m, n, i, a... |
|
|
Invention
|
Mutant kras modulators and uses thereof.
The disclosure includes compounds of Formula (1)-(4) wh... |
|
|
Invention
|
Bcl-2 inhibitors. 123456781234567910111255 are defined herein. Also disclosed is a method for tre... |
|
|
Invention
|
Mutant kras modulators and uses thereof. 123123456123122, m, n, and i, are defined herein. Also d... |
|
|
Invention
|
Bcl-2 inhibitors. The disclosure includes compounds of Formula (A):
4, are defined herein. Also ... |
|
|
Invention
|
Quinuclidinone analogues as anticancer agents.
The disclosure includes compounds of either Formu... |
|
|
Invention
|
Quinuclidinone analogues as anticancer agents. 12341233, m, n, and k are defined herein. Also dis... |
|
|
Invention
|
Condensed heterocyclic derivates as bcl-2 inhibitors for the treatment of neoplastic diseases. Th... |
|
|
Invention
|
Substituted pyrrolopyridines as atr inhibitors.
The disclosure includes compounds of Formula (I)... |
|
|
Invention
|
Spirocyclic mdm2 modulator and uses thereof.
The disclosure includes compounds of Formula (I), w... |
|
|
Invention
|
Spirocyclic mdm2 modulator and uses thereof. 0123456123456122, W, m, n, r, and s, are defined her... |
|
2021
|
Invention
|
1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and aut... |
|
|
Invention
|
Btk degrader.
The disclosure includes compounds of any one of Formulae (0)-(5), (A)-(E), (1)-(V)... |
|
|
Invention
|
Btk degrader. The disclosure includes compounds of any one of Formulae (0)-(5), (A)-(E), (l)-(V),... |
|
|
Invention
|
Inhibitors of btk.
The disclosure includes compounds of Formula (I), or Formula (I) wherein Q0, ... |
|
|
Invention
|
Inhibitors of btk. 02340345677, are defined herein. Also disclosed is a method for treating a neo... |
|
|
Invention
|
Dosage form compositions comprising an inhibitor of btk and mutants thereof.
Provided herewith a... |
|
|
Invention
|
Dosage form compositions comprising an inhibitor of btk and mutants thereof. Provided herewith ar... |
|
|
Invention
|
Hot melt extruded solid dispersions containing a bcl2 inhibitor.
A pro-apoptotic solid dispersio... |
|
|
Invention
|
Hot melt extruded solid dispersions containing a bcl2 inhibitor. A pro-apoptotic solid dispersion... |
|
|
Invention
|
Quinuclidinone analogues as anticancer agents.
The disclosure includes compounds of Formula (I) ... |
|
|
Invention
|
Quinuclidinone analogues as anticancer agents. 1233, m, n, k, and L are defined herein. Also disc... |
|
2020
|
Invention
|
Inhibitor of btk and mutants thereof.
The disclosure includes compounds of Formula (I) wherein Q... |
|
|
Invention
|
Condensed heterocycles as bcl-2 inhibitors.
The disclosure includes compounds of Formula (A) whe... |
|
|
Invention
|
Condensed heterocycles as bcl-2 inhibitors. 1234567891011112345677, are defined herein. Also disc... |
|
|
Invention
|
Inhibitor of btk and mutants thereof.
The disclosure includes compounds of Formula (I) (1) where... |
|
2019
|
Invention
|
1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment... |
|
|
Invention
|
Bcl-2 inhibitors. 7, are defined herein. Also disclosed is a method for treating a neoplastic dis... |
